论文部分内容阅读
〔目的〕分析MVP方案（丝裂霉素十长春花碱酰胺十顺铂）治疗晚期非小细胞肺癌（NSCLC）近期疗效。［方法〕采用MVP方案治疗晚期NSCLC64例，病理分期正ⅢB～Ⅳ期。其中39例为初治，腺癌42例，鳞癌15例，腺鳞瘤1例，未能分型6例。（结果）总有效率32．8％（21／64），中位缓解期4个月，中位生存期6个月，初治者有效率41．0％（16／39）．复治者有效率20．0％（5／25），初治比复治疗效好（P＜0.05）。初治中腺癌有效率39．3％（11／28），鳞癌有效率167％（1／6），两者统计学无显著差异（P＞0．05）。另外，在顺铂几种给药方法中以60mg／m2～80mg／m2一次给药效果好、毒副作用主要以骨髓抑制，胃肠道反应，脱发及末梢神经炎。(结论)MVP方案为治疗晚期NSCLC有效方案，可作为首选方案，但需注意毒副反应，特别是白细胞及血小板减少。采用顺铂大剂量一次给药，可能提高此方案近期疗效。
[Objective] To analyze the short-term efficacy of MVP regimen (mitoarcomic ten vinblastine amide cisplatin) in the treatment of advanced non-small cell lung cancer (NSCLC). [Methods] Sixty-four patients with advanced NSCLC were treated with MVP regimen. The pathological stage was positive in stages IIIB-IV. Thirty-nine of them were untreated, with adenocarcinoma in 42 cases, squamous cell carcinoma in 15 cases, adenosquamous tumor in 1 case, and failure in classification in 6 cases. (Results) The total effective rate was 32.8% (21/64), the median remission period was 4 months, the median survival period was 6 months, and the initial treatment efficiency was 41.0% (16/39). The retreatment rate was 20.0% (5/25), and the initial treatment was more effective than the retreatment (P<0.05). The initial effective rate of adenocarcinoma was 39.3% (11/28), and the effective rate of squamous cell carcinoma was 167% (1/6). There was no statistically significant difference between the two (P>0.05). In addition, in a few administration methods of cisplatin, 60 mg/m2 to 80 mg/m2 is effective at one time, and the toxic and side effects are mainly myelosuppression, gastrointestinal reaction, hair loss and peripheral neuritis. (Conclusion) The MVP regimen is an effective regimen for the treatment of advanced NSCLC and can be used as the first choice, but attention should be paid to toxicity, especially leukopenia and thrombocytopenia. The use of large doses of cisplatin once may increase the short-term efficacy of this regimen.